News | Myriad Genetics

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

Financial

Myriad Genetics Names Pamela Wong as Chief Legal Officer

Corporate

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

Products

Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp

Corporate

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey

Products

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

Financial

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Pipeline

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

Financial

New research reveals most Americans can’t identify the symptoms of depression

Products

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

Corporate

Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions

Corporate

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

Corporate

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

Corporate

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Corporate

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

Corporate